Figure 1.

Sciatic nerve conduction studies in Tr^J mice (a) performed at baseline and end point showed pyruvate (PYR) treatment preserved compound muscle action potential (CMAP) amplitudes during the 16 weeks of treatment period while a significant deterioration occurred in the untreated control Tr^J group (n = 6 in each cohort). PYR and AAV1.NT‐3 combinatorial therapy (PYR + NT‐3; n = 9) significantly improved end point CMAPs and nerve conduction velocities (a and b) (Student’s t‐ test; *p < 0.05). End point motor functions at 16 weeks were tested by performing hind‐limb grip strength (c) and four‐limb wire hanging test (d). Both PYR (n = 6) and PYR + NT‐3 group (n = 9) performed better than control group (n = 6) in both test (one‐way ANOVA for B and C; *p < 0.05, **p < 0.01). Error bars represent standard error of means